HAEMONETICS CORP
Haemonetics is a medical technology company that serves biopharmaceutical companies, blood collection organizations, hospitals and hospital service providers, among other customers. It operates through three segments: Plasma, Blood Center and Hospital. Plasma offers automated source-plasma collection devices, disposables, donor management software and related support for plasma collection centers. Blood Center supplies automated blood-component collection equipment and related products to blood centers. Hospital serves clinicians and hospitals with interventional technologies, including vascular closure and sensor-guided products, and blood management technologies for hemostasis, cell salvage and transfusion management. Haemonetics makes money by selling medical devices, disposables, software and services. Its products include NexSys PCS plasma collection systems, MCS apheresis equipment, VASCADE vascular closure devices, TEG hemostasis diagnostic systems, Cell Saver Elite+ blood recovery systems and transfusion management software. It markets and sells its products in approximately 90 countries through its direct sales force and independent distributors. Haemonetics is headquartered in Boston, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HAE in the last 30 days.
See all $HAE insider activity →Citigroup kept its Buy rating on Haemonetics and increased its price target to $149 from $123, citing a 24.2% upside from the Nov 6 close. Recent analyst targets range from $140 to $145.
Barrington Research maintained its Outperform rating on Haemonetics and raised its price target to $145 from $140, implying a 16.8% upside from the Nov 5 close of $124.11. Recent analyst price targets for Haemonetics range from $140 to $142.
Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning HAE (HAEMONETICS CORP). Coverage has skewed bullish: 17 bullish, 0 neutral, and 2 bearish.
Recent HAE coverage spans earnings, financial news and regulation.
Citigroup kept its Buy rating on Haemonetics and increased its price target to $149 from $123, citing a 24.2% upside from the Nov 6 close. Recent analyst targets range from $140 to $145.
Analyst upgrade may drive buying interest and price appreciation.
Guidance cut and higher costs suggest downside risk.
Analyst upgrades suggest bullish pressure on the stock.
Analyst upgrade suggests upside potential.
AlphAI scores every news story that mentions HAE with an AI model for sentiment and relevance, and aggregates insider trades from HAEMONETICS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Citigroup kept its Buy rating on Haemonetics and increased its price target to $149 from $123, citing a 24.2% upside from the Nov 6 close. Recent analyst targets range from $140 to $145.
Barrington Research maintained its Outperform rating on Haemonetics and raised its price target to $145 from $140, implying a 16.8% upside from the Nov 5 close of $124.11. Recent analyst price targets for Haemonetics range from $140 to $142.
Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.
Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.
BTIG reaffirmed its Buy rating for Haemonetics and increased its price target to $142 from $130, suggesting a 11.4% upside from the Nov 4 close of $127.42. Recent analyst price targets for the company range from $130 to $140.
Haemonetics reported Q2 2026 revenue of $357.76M, up 9.3% YoY, and net income of $46.31M, up 19.7% YoY. Growth was driven by volume increases and market share gains in Plasma and MedSurg. Gross margin improved to 61.7% from 59.5%. CSL may use NexSys PCS devices, though details are pending.
HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Sr. Manager-Investor Rel
Haemonetics (HAE) received FDA approval for a product, boosting its outlook. The stock surged past a buy point of 81.99 in July and formed a three-weeks-tight pattern, offering an entry at 123.77. The company is set to report earnings soon.
Nasdaq rose 1.11% while Dow slipped 0.07%, with S&P 500 up 0.66%. VIX fell 1.55 points. Lockheed Martin delivered a C-130J-30 to the U.S. Navy. F.N.B. reported Q3 net income of $152.9M. Haemonetics got FDA approval for PerQseal Elite. Zions Bancorporation Q3 earnings rose 20% YoY. Crown Holdings Q3 EPS up to $2.08.
Haemonetics (HAE) received FDA approval for the PerQseal Elite vascular closure system, expanding its U.S. portfolio after acquiring Vivasure in 2026. The approval is a step in the company's execution following the acquisition, according to AI Analyst.
